United Therapeutics (UTHR) Tops Q1 EPS Views; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $507.90 +1.63%
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $1.32, $0.39 better than the analyst estimate of $0.93. Revenue for the quarter came in at $204.2 million versus the consensus estimate of $203.91 million.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Benchmark Reiterates Buy Rating on Odysight.AI Inc. (ODYS)
- INVO Fertility (IVF) Tops Q2 EPS by 105c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
